2026年3月期第3四半期決算説明会資料

This document is a presentation material regarding the consolidated financial results for the third quarter of the fiscal year ending March 2026 for Transgenic Group Inc. The drug discovery support business recorded a 17.2% increase in revenue compared to the same period last year, with significant improvements in profitability. Meanwhile, the investment and consulting business experienced a decrease in revenue but achieved an increase in profit due to improvements in gross profit margins. The document also discusses the results of GLP compliance investigations and measures to prevent recurrence. Overall, it outlines the growth strategy while considering risks associated with changes in the business environment.